EMEA-001912-PIP02-16-M03 - paediatric investigation plan

angiotensin II (LJPC-501)
PIP Human

Key facts

Invented name
Giapreza
Active substance
angiotensin II (LJPC-501)
Therapeutic area
Cardiovascular diseases
Decision number
P/0415/2023
PIP number
EMEA-001912-PIP02-16-M03
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of hypotension associated with distributive or vasodilatory shock
Route(s) of administration
Intravenous use
Contact for public enquiries

PAION Deutschland GmbH

Tel. +49 241 44530
E-mail: info@paion.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
No

Decision

Share this page